Binod Dhakal, MD, MS

Articles by Binod Dhakal, MD, MS

Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment

ByBinod Dhakal, MD, MS,Joseph R. Mikhael, MD,Cindy Varga, MD,Beth Faiman, PhD, CNP,Jeremy Larsen, MD

May 31st 2023

Dr Cindy Varga discusses recent data on the FDA-approved agent teclistamab, a bispecific antibody for patients with relapsed/refractory multiple myeloma.

Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)

ByBinod Dhakal, MD, MS,Joseph R. Mikhael, MD,Cindy Varga, MD,Beth Faiman, PhD, CNP,Jeremy Larsen, MD

May 31st 2023

Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.

Binod Dhakal, MD, MS

Articles by Binod Dhakal, MD, MS

Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment

Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)

Trending on CancerNetwork

Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026

CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma

Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC

FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer

NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma